Interview: Has UK Medtech Happened Upon A Perfect Opportunity For Disruptive Regulatory Change?
The UKCA mark and new device legislation could open doors onto a bigger global role for the MHRA
ABHI’s Phil Brown looks beyond the immediate challenges for UK medtechs on being outside the EU, and to an innovation-friendly, patient-responsive system of future regulation.
You may also be interested in...
With the UK implementing sovereign device legislation after leaving the EU, there are opportunities for incorporating updated EU and US FDA provisions as regulation evolves.
The Cumberlege Review of patient safety delivered a damning verdict on the UK’s health system. Its recommendations must be acted on, says a consensus of stakeholders.
New MHRA guidance says the EU CE marking will continue to be used for devices and diagnostics in Great Britain until June 2023, and thereafter a standalone regulatory system will come into place.